REYNO LEONARD
Transaction: 07/10/2026
SELL
Change
-7,397
Price
$4.06
Filing
07/13/2026
Type
SELL
C4 Therapeutics, Inc.
CCCC • Biotechnology
$3.76
▲ +0.02 (+0.53%)
Current price
EarningsLatest report: Jun 30, 2026
HIGHER-RISK PROFILECautionConfidence: 70%
Quantitative profile — not an investment recommendation.
Quantitative profile — not an investment recommendation.Methodology
Analysis thesis: Caution is warranted. Recent ratios show weaknesses that may limit returns unless fundamentals improve.
Market Cap
$491.42M
Growth
-14.6%
Cash Flow
0/5
Trend
Negative
Evidence
Manageable debt level · 0.23Healthy liquidity · 7.81Negative growth trendWeak profitability
Financial data as of: Jun 30, 2026, 12:00 AM UTCLast earnings update: Jun 30, 2026, 12:00 AM UTCLast profile update: Aug 13, 2026, 12:12 PM UTC
Company Snapshot
Key valuation, quality, financial strength, momentum and analyst data.
Price$3.76
Change0.53%
Shares Out130.70M
Market Cap$491.42M
Enterprise Value$294.61M
52W Range1.69 - 5.17
Beta2.95
P/E-4.85
P/S14.02
P/B1.99
P/FCF-5.75
EV/Sales8.41
Price$3.76
Change0.53%
Shares Out130.70M
Market Cap$491.42M
Enterprise Value$294.61M
52W Range1.69 - 5.17
Beta2.95
P/E-4.85
P/S14.02
P/B1.99
P/FCF-5.75
EV/Sales8.41
EV/EBITDA-2.84
EV/FCF-3.45
Earnings Yield-20.64%
FCF Yield-17.38%
Dividend Yield0.00%
Gross Margin77.81%
Oper. Margin-2.91%
Profit Margin-2.92%
Debt/Eq0.23
Current Ratio7.81
Quick Ratio7.81
Revenue 5Y-14.60%
Target$11.33
Target Upside201.33%
Target Median$10.00
Target Range6.00 - 20.00
Volume1.96M
Avg Volume3.14M
EPS Surprise0.05
Investment DNA
How strong this company looks for long-term investors
40
out of 100
Business Quality
Margins, moat, returns
22/100
Financial Strength
Debt, cash, stability
76/100
Growth Potential
Revenue and expansion
20/100
Price Attractiveness
Cheap or expensive today
81/100
Why this score▼
Manageable debt level · 0.23Healthy liquidity · 7.81Negative growth trendWeak profitability
Analyst view
Analyst sentiment and price target
Analyst sentiment
Based on 14 analyst votes · 2026-09-05
82/100
Bullish
Bullish
10
Hold
3
Bearish
1
Price Target
2026-08-13
Low
$7.00
Mean
$7.00
Median
$7.00
High
$7.00
Insider Transactions
Recent executive and insider activity
GROGAN DONNA ROY
Transaction: 07/01/2026
BUY
Change
+3,341
Price
$4.34
Filing
07/02/2026
Type
BUY
Anderson Kenneth Carl
Transaction: 07/01/2026
BUY
Change
+2,650
Price
$4.34
Filing
07/02/2026
Type
BUY
| Insider | Type | Change | Price | Transaction | Filing |
|---|---|---|---|---|---|
| REYNO LEONARD | SELL | -7,397 | $4.06 | 07/10/2026 | 07/13/2026 |
| GROGAN DONNA ROY | BUY | +3,341 | $4.34 | 07/01/2026 | 07/02/2026 |
| Anderson Kenneth Carl | BUY | +2,650 | $4.34 | 07/01/2026 | 07/02/2026 |
| GROGAN DONNA ROY | BUY | +62,000 | $4.25 | 06/24/2026 | 06/26/2026 |
| Fawell Stephen | BUY | +62,000 | $4.25 | 06/24/2026 | 06/26/2026 |
| Bessen Laura | BUY | +62,000 | $4.25 | 06/24/2026 | 06/26/2026 |
| Cooper Ronald Harold Wilfred | BUY | +62,000 | $4.25 | 06/24/2026 | 06/26/2026 |
| Anderson Kenneth Carl | BUY | +62,000 | $4.25 | 06/24/2026 | 06/26/2026 |
| Koppikar Utpal | BUY | +62,000 | $4.25 | 06/24/2026 | 06/26/2026 |
| Hoerter Steven L. | BUY | +62,000 | $4.25 | 06/24/2026 | 06/26/2026 |
| Hughes Owen | BUY | +62,000 | $4.25 | 06/24/2026 | 06/26/2026 |
| Anderson Kenneth Carl | SELL | -1,070 | $2.11 | 06/01/2026 | 06/04/2026 |
| Anderson Kenneth Carl | BUY | +1,070 | $2.11 | 06/01/2026 | 06/04/2026 |
| GROGAN DONNA ROY | BUY | +5,370 | $2.70 | 04/01/2026 | 04/03/2026 |
| Anderson Kenneth Carl | BUY | +4,259 | $2.70 | 04/01/2026 | 04/03/2026 |
| Hirsch Andrew | SELL | -9,057 | $1.89 | 02/15/2026 | 02/18/2026 |
| Mossler Mark | SELL | -3,268 | $1.89 | 02/14/2026 | 02/18/2026 |
| Adams Kendra | SELL | -15,381 | $1.89 | 02/14/2026 | 02/18/2026 |
| REYNO LEONARD | SELL | -16,579 | $1.89 | 02/14/2026 | 02/18/2026 |
| Hirsch Andrew | SELL | -39,154 | $1.89 | 02/14/2026 | 02/18/2026 |